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Abstract
Objectives This study aimed to investigate the impact of newly introduced clinical pharmacy serv-
ices on the health care of chronic haemodialysis patients attending an outpatient haemodialysis 
unit in a rural hospital with limited resources in Alexandria, Egypt.
Methods A quasi-experimental pre-/post-test study was conducted from November 2016 till June 
2018. Clinical pharmacists collected relevant information using a pre-specified form. Patients’ data 
were reviewed for drug-related problems (DRPs), which were documented using the Pharmaceutical 
Care Network Europe (PCNE) classification system, version 8.02 and resolved by the clinical phar-
macists. Measured values of calcium, phosphorus and haemoglobin were compared with target 
levels set by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Proportions 
of patients achieving therapeutic values of each parameter were compared before and after 
implementing the program using the McNemar test. We also reported the analysis of DRPs identi-
fied and addressed by the clinical pharmacy team.
Key findings A total of 685 DRPs were identified during the follow-up period. Improper dose and 
inappropriate drug selection were the most common DRPs (45.8% and 18.9%, respectively). There 
was a statistically significant increase in the proportion of patients achieving target corrected cal-
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levels (9.1% pre-intervention versus 31.9% post-intervention, P = 0.003), but not in phosphorus 
levels (18.6% pre-intervention versus 22% post-intervention, P = 0.7).
Conclusions Clinical pharmacists were able to resolve frequent DRPs and improve some markers 
of health care in haemodialysis patients.
Keywords: clinical pharmacy; corrected calcium; haemoglobin; drug-related problems; haemodialysis
Introduction
Haemodialysis patients are at an increased risk of developing 
comorbidities and complications due to their advanced renal disease 
and associated renal replacement therapy. Such a complicated health 
state often requires multiple medications which can subsequently im-
pact how patients comply with their prescribed medication regimens 
and predispose them to drug-related problems (DRPs).[1, 2] Furthermore, 
psychological and socioeconomic factors impose an additional burden 
on haemodialysis patients, their care providers and healthcare systems. 
However, evidence suggests that improvements brought about by ad-
vances in dialysis modalities and technologies, as well as manoeuvres 
for better medical management can help improve the clinical outcomes 
of haemodialysis patients.[3–5] For example, rigorous compliance with 
the guidelines for managing common conditions like anaemia, mineral 
bone disease (MBD) and hypertension was associated with a reduction 
in all-cause mortality among haemodialysis patients in a large cohort 
of European dialysis patients (EURODOPPS).[4] Evidence also suggests 
that certain pharmacological interventions may improve cardiovascular 
outcomes in haemodialysis patients.[5]
In addition to the pharmacological interventions, advances in 
healthcare systems have also been associated with improved pro-
cesses and outcomes in haemodialysis patients. For example, the 
adoption of an integrated care model provided by the Medicare 
Advantage program was associated with 9% reduction in mor-
tality when compared with usual care.[6] Similarly, the adoption of 
a multidisciplinary team with the integration of allied healthcare 
providers including pharmacists, dietitians and social workers has 
led to improved care for haemodialysis patients.[7–9] Pharmacists, 
as members of the multidisciplinary team, can conduct medi-
cation reconciliation, reduce medication errors and improve pa-
tients’ adherence to the usually complex medication regimens in 
haemodialysis patients.[10–13] Evidence suggests that pharmacist-led 
medication review was associated with better identification and 
resolution of DRPs.[14–16] Furthermore, the provision of clinical 
pharmacy services to haemodialysis patients led to improvement 
in healthcare outcomes and better management of anaemia and 
MBD.[17–19]
Although clinical pharmacy services have been widely provided 
to haemodialysis patients in many countries including the USA, some 
European and some Middle Eastern countries, such services have 
only been introduced recently in many other countries including 
Egypt.[20–22] Furthermore, financial constraints coupled with lack of 
basic healthcare services including access to essential drugs and in-
vestigations pose a significant challenge in the implementation of 
effective services to patients and may interfere with the quality of 
care provided to haemodialysis patients. To the authors’ knowledge, 
no studies have been conducted to assess the impact of clinical phar-
macy services on adult haemodialysis patients in Egypt. This study, 
therefore, aimed to investigate the impact of introducing a clinical 
pharmacy services program (CPSP) on selected healthcare outcomes 
of patients attending a haemodialysis unit in a rural hospital in 
Alexandria, Egypt.
Methods
Study design, population and setting
A quasi-experimental pre-/post-test study was conducted in a haemo-
dialysis unit of a rural hospital in Alexandria, Egypt. All patients 
above the age of 18 attending the haemodialysis unit from August 
2016 till June 2018 were included. The CPSP implementation began 
in November 2016 and continued till June 2018. Figure 1 illustrates 
the timeline of the study.
Ethical approval
Ethical approval was obtained from the Ministry of Health Research 
Ethics Committee (17-2018/9).
Data collection
A data collection form was developed, using previous literature,[23] 
and tailored to provide optimal utility for both clinical and research 
purposes. The form was used to collect relevant patients’ informa-
tion from medical records and patient interviews conducted by the 
clinical pharmacists. The data included patient demographics, med-
ical history, medication history, dietary habits, laboratory data, vital 
signs, information about dialysis sessions, medicines adherence and 
lifestyle modifications.
Study intervention
During the program implementation period, pharmacists provided 
clinical pharmacy services, including identification and resolution of 
DRPs, patient education about renal disease and haemodialysis, life-
style modifications and basic self-monitoring skills. DRPs identified 
and resolved by the clinical pharmacists during the study period were 
documented and classified using the Pharmaceutical Care Network 
Europe (PCNE) system, version 8.02.[24] Each problem was described 
according to four major domains: problem type, cause, intervention 
type and intervention acceptance.
Outcome measures
Calcium and phosphorus blood levels were used as indicators for 
MBD control. Meanwhile, haemoglobin concentration was used 
Figure 1 Timeline of the study. 1, August 2016; 2, October 2016; 3, November 
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as the indicator for anaemia control. Measured values were com-
pared with target levels set by the Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines, which recommended target 
haemoglobin levels ranging between 10 and 11.5 g/dL, and cor-
rected calcium and phosphorus levels within the normal range of 
each.[25, 26] Due to financial constraints, costly laboratory tests like 
parathyroid hormone (PTH) levels, iron indices were not always 
performed at the intervals recommended by the KDIGO guide-
lines, making the available data not enough to be used as outcome 
measures. Proportions of patients achieving therapeutic values of 
each parameter were compared before and after implementing the 
program. Since the KDIGO guidelines recommend that decisions 
to initiate or modify medication treatments should be based on 
trends in laboratory values rather than a single measurement,[25] 
the pre-intervention values were the average of values collected 
throughout the 3-month period that preceded initiating the pro-
gram and the post-intervention values were estimated by aver-
aging the values of each parameter in the last 3  months of the 
intervention as shown in Figure 1.
Statistical analysis
Shapiro–Wilk test was conducted to test for normality of continuous 
variables. The data were not normally distributed and were, there-
fore, described as medians and interquartile ranges. Categorical 
variables were described as numbers and percentages. McNemar 
test was applied for comparing the proportions of patients achieving 
target laboratory values pre- and post-program implementation. All 




We followed up a total of 51 patients throughout the study period. 
The patients’ median age was 55 years with a median body mass 
index (BMI) of 27.3 kg/m2. Table 1 presents an overview of the pa-
tients’ demographics and common comorbidities.
Assessment of outcome measures
Regarding the laboratory markers, the proportion of patients who 
achieved target corrected calcium levels was significantly higher 
after implementing the program (30% pre-intervention versus 
69.6% post-intervention, P  =  0.001), and that was also the case 
for haemoglobin levels (9.1% pre-intervention versus 31.9% post-
intervention, P = 0.003). The proportion of patients who achieved 
target phosphorus levels was higher after the program, however, the 
increase did not reach statistical significance (18.6% pre-intervention 
versus 22% post-intervention, P = 0.7). Figure 2 demonstrates the 
proportions of patients whose values were in therapeutic range pre- 
and post-CPSP implementation.
DRPs identification, resolution and acceptance
During the follow-up, a total of 685 DRPs was identified by the clin-
ical pharmacists. When DRPs were classified by type, treatment ef-
fectiveness problems were the most common type (n = 294, 42.9%), 
and when they were classified by cause, improper dose selection was 
the most common cause (n  =  314, 45.8%), followed by inappro-
priate drug selection (n = 130, 19%). Expectedly, since most DRPs 
were caused by improper dose or drug selection, the majority of the 
clinical pharmacists’ interventions was made at the prescriber’s level 
(n = 499, 72.8%). Eighty-five percent of the interventions the clinical 
pharmacist made to resolve DRPs during the follow-up period were 
accepted. A detailed classification of the identified DRPs using the 
PCNE V 8.02 system is provided in Table 2.
Discussion
We found that the introduction of a CPSP to the haemodialysis unit 
in a hospital located in a rural area was associated with improve-
ment in the proportion of haemodialysis patients who achieved the 
target values of laboratory markers that reflect the management of 
MBD and anaemia[25, 26] and was also associated with the resolution 
of many DRPs in this sensitive population.
MBD is a common problem in haemodialysis patients that is 
associated with numerous complications including increased risk of 
fractures and vascular calcification, which are independently associ-
ated with increased morbidity and mortality. Thereby, maintaining 
target levels of corrected calcium, phosphorus and PTH has been 
linked to improved survival in haemodialysis patients.[25] Our study 
showed that the CPSP was associated with significant improvement 
in the proportion of patients achieving target corrected calcium 
levels. The interventions provided as part of the CPSP included stop-
page of vitamin D analogues that were not indicated, adjusting the 
dose of calcium-containing phosphate binders and patient educa-
tion about diet and bone health. However, the improvement in the 
Table 1 Descriptive characteristics of the study population, median 
(IQR) or N (%)
Characteristic Median (IQR) or N (%)
Number of patients 51
 Male 28 (54.9%)
 Female 23 (45.1%)
Age (years) 55 (43–60)
BMI (kg/m2) 27.3 (23–31)
Dialysis vintage (years) 5 (3–7)
Comorbidities
 Hypertension 35 (68.6%)
 Diabetes 10 (19.6%)
 HCV 10 (19.6%)
 Cardiovascular disease 4 (7.8%)
HCV, hepatitis C virus; IQR, interquartile range.
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proportion of patients achieving target phosphorus levels was not 
statistically significant.
Some of our findings are in line with the findings of previous 
studies. For example, a large retrospective cohort by Roberts-Clary 
et al. examined the association between the implementation of coor-
dinated pharmacy services and the achievement of target values for 
MBD management parameters and found that patients who received 
pharmacy services achieved target calcium, phosphorus, PTH more 
often than their propensity score-matched controls.[27] On the other 
hand, a pre-/post-test study conducted by Baker et al. found no sig-
nificant improvement in MBD parameters to be associated with the 
implementation of a patient-centred, pharmacist–dietician-led man-
agement approach.[28]
Anaemia is associated with cardiovascular complications, hos-
pitalization and death in haemodialysis patients. The current guide-
lines recommend attaining specific values of haemoglobin, ferritin 
and transferrin saturation (TSAT) to optimize the management of 
anaemia in dialysis patients.[26] In our study, we included the propor-
tion of patients achieving target haemoglobin levels as a measure for 
anaemia control, however, we were not able to assess the attainment 
of target ferritin and TSAT levels as these tests were not performed 
in our hospital’s routine laboratory workup. Nevertheless, clinical 
pharmacists ensured that each patient had their ferritin and TSAT 
checked at baseline to determine their eligibility for an iron load. 
Indeed, most of the patients were severely iron deficient and received 
loading doses of iron, followed by twice-monthly maintenance 
doses. Once iron status was corrected, many patients showed re-
markable improvement in their haemoglobin levels, which was then 
followed by adjusting their erythropoietin-stimulating agent (ESA) 
doses. The CPSP implementation was able to demonstrate a signifi-
cant improvement in the proportion of patients achieving target 
haemoglobin levels. However, the overall percentage of patients with 
controlled haemoglobin levels was not high (around 32%).
Our results, showing a positive impact of the CPSP on the man-
agement of anaemia in haemodialysis patients, came in accordance 
with the results of other studies that show improved haemoglobin 
levels. Additionally, some of these studies showed improvements in 
other anaemia management parameters like TSAT and ferritin.[17–19]
As shown in the results, most of the DRPs affected treatment 
effectiveness and were caused by either suboptimal drug dosing or 
selection. One example of common DRPs was the presence of sig-
nificant iron deficiency at baseline in a patient receiving maximal 
doses of ESA covered by the insurance plan. Subsequently, iron and 
haemoglobin profiles were significantly improved after receiving an 
intravenous iron load followed by maintenance doses even in those 
with insufficient doses of ESA. It is not uncommon that some pa-
tients even required a significant ESA dose reduction after that inter-
vention. The preceding example may explain why most interventions 
were on the prescriber’s level, although one of the basic domains of 
the CPSP was patient education. Furthermore, most of the clinical 
pharmacist recommendations were accepted (85%), indicating ap-
propriate collaboration among physicians, pharmacists and patients 
throughout the program implementation period.
Providing care to haemodialysis patients is usually complex and 
requires multiple resources, including equipment, investigations, 
medications and staff.[9] Although evidence suggesting a positive im-
pact of introducing clinical pharmacy services to haemodialysis pa-
tients existed,[14, 17, 26, 27, 29] it was not clear if these conclusions could 
be extrapolated to settings with significant financial constraints that 
may cause shortages in the supply of medications, lack of proper 
follow-up as well as the low income of the patients rendering them 
incapable of maintaining their medications. For instance, Ohnishi 
et  al. examined the effect of pharmacist management on haemo-
globin levels in haemodialysis patients by developing and applying 
a hospital-specific protocol for dose adjustments of ESAs and iron 
products based on haemoglobin, TSAT and ferritin levels.[17] It re-
sulted in a significant increase in haemoglobin levels in the low-
haemoglobin group and a significant decrease in haemoglobin levels 
in the high-haemoglobin group. While our results come in line with 
some findings in that study, TSAT and ferritin levels were not al-
ways available in our setting. They were only measured at base-
line in most patients to determine the patient’s eligibility for iron 
loading and maintenance doses. Moreover, a study conducted in Iran 
by Dashti et al. encountered some of the barriers we faced in our 
study, like the unavailability of other phosphate binders than cal-
cium carbonate in the government insurance program.[19] However, 
Table 2 Classification of identified drug-related problems using the PCNE V 8.02 system
Classification of problem (total number of interventions) Code and description Frequency and percentage
PCNE V8.02 classification of DRPs by problem type (685) P1: Treatment effectiveness 294 (42.9)
P2: Treatment safety 193 (28.2)
P3: Others 198 (28.9)
PCNE V8.02 classification of DRPs by cause (685) C1: Drug selection 130 (18.9)
C2: Drug form 3 (0.43)
C3: Dose selection 314 (45.83)
C4: Treatment duration 2 (0.29)
C5: Dispensing 5 (0.73)
C6: Drug use/process 5 (0.73)
C7: Patient-related 107 (15.9)
C8: Other 119 (17.37)
PCNE V8.02 classification of DRPs by planned intervention (685) I0: No intervention 1 (0.147)
I1: At prescriber level 499 (72.78)
I2: At patient level 180 (26.33)
I3: At drug level 0
I4: Other 5 (0.74)
PCNE V8.02 classification of DRPs by intervention acceptance (685) A1: Accepted 583 (85)
A2: Not accepted 90 (13.2)
A3: Other 12 (1.74)
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laboratory parameters were measured regularly, and medications 
were adjusted accordingly. The results showed an optimization of 
calcium blood levels and a decrease in phosphorus levels without 
achieving target levels.
Although clinical pharmacy curricula have been incorporated 
into pharmacy education and the number of pharmacists holding 
postgraduate degrees or certificates has been on the rise over the past 
two decades, the recognition of pharmacists as patient care providers 
has been relatively slow at practice settings. In 2013, the Egyptian 
Ministry of Health has declared that establishing clinical pharmacy 
departments in all hospitals was mandatory and clinical pharmacists 
had a better chance to assume their roles in patient care.[22, 30] To the 
authors’ knowledge, this is the first study that has highlighted the role 
of clinical pharmacists in managing adult haemodialysis patients in 
a healthcare setting with limited resources in Egypt. The favourable 
outcomes reported in this study should encourage wider implemen-
tation of clinical pharmacy services in public haemodialysis units.
This study, however, comes with some limitations. It was con-
ducted in a single centre which might prevent the generalization of its 
results to other units adopting different systems. Moreover, the small 
sample size might have prevented the detection of a statistically sig-
nificant difference for phosphorus level improvement. Furthermore, 
we were not able to follow-up some important laboratory param-
eters like iron status, PTH and vitamin D levels for all patients on 
regular bases due to the financial constraints highlighted earlier.
Although patient-reported outcomes – such as patient-reported 
symptoms – are being advocated for their ability to demonstrate pa-
tients’ perspectives; and hard clinical outcomes – such as mortality 
or morbidity end points – are known to provide stronger evidence of 
the presence or absence of efficacy of interventions,[28, 31, 32] surrogate 
parameters like electrolyte and haemoglobin levels were used to de-
rive the end points in this study because they had a well-established 
clinical utility and their management was within the clinical phar-
macists’ scope of practice. Moreover, as mentioned in the discus-
sion section, better control of MBD and anaemia is associated with 
better clinical outcomes such as reduced mortality and hospitaliza-
tions, as well as better quality of life for haemodialysis patients.[33] 
Pharmacoeconomic outcomes were not addressed in the study due 
to excessive complexity in cost measurement since patients, in some 
instances, paid for some laboratory investigations and medications. 
More studies are needed in the future to explore more aspects in 
which clinical pharmacists can add value to patient care processes 
and outcomes.
Conclusion
The introduction of clinical pharmacy services to the haemodialysis 
unit was associated with significant improvement in the propor-
tion of patients who achieved target levels of corrected calcium and 
haemoglobin and numerical improvement in the proportion of pa-
tients achieving target phosphorus levels. The modest improvement 
in the achievement of target phosphorus levels denoted the need for 
further educational efforts about dietary modifications. Moreover, 
effective phosphate-lowering medications such as non-calcium-
containing phosphate binders were not accessible at the time of the 
study, because they were not included in the Ministry of Health for-
mulary. Additionally, the relatively low final percentage of patients 
achieving target haemoglobin levels may be attributed to the incon-
sistent availability of iron injections as well as the lack of sufficient 
ESAs doses covered by the patients’ insurance program. Moreover, 
the majority of patients could not afford the high prices of ESAs on 
their own.
Clinical pharmacists were able to detect and resolve several 
DRPs that could adversely impact patient outcomes.
These findings support the evidence on the vital role of clinical 
pharmacists in improving the care provided to haemodialysis pa-
tients in settings with economic constraints and should encourage 
enabling pharmacists to assume wider roles as patient care providers 
and to incorporate them into decision-making process of establishing 
institutional and national drug formulary. Future research should be 
directed to assess more aspects of patient care associated with the 
introduction of CPSP in healthcare systems with financial challenges.
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